van Schaik, Ron H N <br/><br/>
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.  [electronic resource] 

 -  Pharmacogenomics  Aug 2011 
 - 1137-46 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1744-8042 
<br/><br/><label>Standard No.: </label>10.2217/pgs.11.54  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Aryl Hydrocarbon Hydroxylases--genetics<br/>Breast Neoplasms--drug therapy<br/>Combined Modality Therapy<br/>Cytochrome P-450 CYP2C19<br/>Cytochrome P-450 CYP2D6--genetics<br/>DNA, Neoplasm--genetics<br/>Data Interpretation, Statistical<br/>Female<br/>Follow-Up Studies<br/>Genotype<br/>Humans<br/>Lymphatic Metastasis--pathology<br/>Menopause<br/>Middle Aged<br/>Pharmacogenetics<br/>Predictive Value of Tests<br/>Prognosis<br/>Receptors, Progesterone--metabolism<br/>Retrospective Studies<br/>Survival Analysis<br/>Tamoxifen--therapeutic use<br/>Treatment Outcome